Author

J. Catalano

Observed name: J Catalano

Institution: Frankston Hospital

Observed institutions: Cleveland Clinic, The Royal Melbourne Hospital, Royal Marsden NHS Foundation Trust, Mayo Clinic, Peter MacCallum Cancer Centre, Monash Medical Centre, Frankston Hospital, Monash Health, Royal Marsden Hospital, Celgene (United States)

OpenAlex ID: A5113989391

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

2010 · M Hallek, K Fischer, et al. · The Lancet · 1,888

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

2011 · H. Iland, K. Bradstock, et al. · Haematologica · 57

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.

2003 · Robert Marcus, Kevin Imrie, et al. · Ghent University Academic Bibliography (Ghent University) · 41

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

2011 · S. Verstovsek, R. A. Mesa, et al. · Journal of Clinical Oncology · 40

Results of a Double Blind Placebo Controlled Study of Ondansetron as an Antiemetic During Total Body Irradiation in Patients Undergoing Bone Marrow Transplantation

1992 · C. Tiley, R. Powles, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 32

Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.

2011 · A. P. Palumbo, M. Delforge, et al. · Journal of Clinical Oncology · 27

Tumour Lysis Following Hydrocortisone Prior to a Blood Product Transfusion in T-Cell Acute Lymphoblastic Leukaemia

1992 · C. Tiley, D. Grimwade, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 26

A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM)

2010 · Antonio Palumbo, Meletios Α. Dimopoulos, et al. · 20

A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma

2006 · S. V. Rajkumar, M. Hussein, et al. · Journal of Clinical Oncology · 20

Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia.

1993 · C Tiley, R Powles, et al. · PubMed · 13

LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL

2014 · Thierry Façon, Meletios Α. Dimopoulos, et al. · Haematologica · 5

Health Resource Utilization with Continuous Lenalidomide Treatment (TX) in Elderly Patients (PTS) with newly diagnosed multiple myeloma (NDMM)

2015 · K. Weisel, D. Vogl, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Health Resource Utilization With Continuous Lenalidomide Treatment (tx) in Elderly Patients With Newly Diagnosed Multiple Myeloma (ndmm)

2015 · K. Weisel, DT Vogl, et al. · Haematologica · 1

Updated results of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to immunochemotheraphy

2010 · Gilles Salles, J. Catalano, et al. · University of Southern Denmark Research Portal (University of Southern Denmark)

Quality of life (QOL) assessment in patients with relapsed/refractory multiple myeloma (MM) treated with thalidomide (T) plus celecoxib (Cxb)

2005 · L. R. Mileshkin, A. Roberts, et al. · Journal of Clinical Oncology

Works count: 16

Citation count: 2,171

H-index: 10

I10-index: 10